Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens

Beelen, Dietrich W.; Markiewicz, Mirosław; Stelljes, Matthias; Reményi, Péter; Wagner‐Drouet, Eva‐Maria; Dreger, Peter; Bethge, Wolfgang; Ciceri, Fabio; Stölzel, Friedrich; Junghanß, Christian; Michallet, Mauricette; Schaefer‐Eckart, Kerstin; Grigoleit, Goetz Ulrich; Scheid, Christof; Micò, Maria Caterina; Niederwieser, Dietger; Hilgendorf, Inken; Russo, Domenico; Socié, Gérard; Holler, Ernst; Glaß, Bertram; Wulf, Gerald; Basara, Nadežda; Hellmann, Andrzej; Stuhler, Gernot; Verbeek, Mareike; Iori, Anna Paola; Finke, Jürgen; Benedetti, Fabio; Casper, Jochen

doi:10.1016/j.bbmt.2018.12.685

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of a randomized trial comparing treosulfan-fludarabine vs busulfan-fludarabine in adult AML and MDS patients ineligible for standard MAC regimens (NCT00822393), reported in abstract form, have demonstrated a significant improvement in OS after treosulfanbased conditioning. 32 This benefit was primarily attributed to the reduction in TRM while preserving antileukemic efficacy.…”

Section: Allogeneic Hsctmentioning

confidence: 99%

In MDS, is higher risk higher reward?

Sanz

2019

Hematology

View full text Add to dashboard Cite

Patients with higher-risk myelodysplastic syndrome (HR-MDS) are defined by the original or revised International Prognostic Scoring System and specific genetic features. Treatment of HR-MDS is challenging. Allogeneic hematopoietic stem cell transplantation, the only curative approach, is feasible in a minority of fit or intermediate fitness patients aged <70 to 75 years who are willing to face the risks of the procedure. Response to azacitidine and decitabine, the only approved drugs for HR-MDS and considered the standard of care, is partial and transient in most patients. The development of novel more personalized and efficient drugs is an unmet medical need. During the last decade, there have been substantial advances in understanding the multiple molecular, cellular, and immunological disturbances involved in the pathogenesis of myelodysplastic syndrome. As a result, a number of clinical and translational studies of new more focused treatment approaches for HR-MDS patients are underway. In contrast to acute myeloid leukemia, they have not resulted in any new drug approval. This review addresses the benefits and limitations of current treatment alternatives, offers a practical individualized treatment approach, and summarizes the clinical trials in progress for HR-MDS.

show abstract

Section: Allogeneic Hsctmentioning

confidence: 99%

In MDS, is higher risk higher reward?

Sanz

2019

Hematology

View full text Add to dashboard Cite

show abstract

“…Towards improving conditioning regimens, there was a large multi-center Phase III study from Europe that compared the use of treosulfan in place of busulfan in the setting of a RIC conditioning regimen for older patients and those not eligible to receive a full myelo-ablative conditioning regimen which clearly established the statistically significant advantage of the treosulfan based regimen on event free survival (EFS) and overall survival (OS) [4]. Another relatively novel approach was the use of time sequential conditioning regimens with targeted dose busulfan and post-transplant cyclophoshamide graft versus host disease (GVHD) prophylaxis, building on the earlier experience by this group with this regimen [5].…”

Section: Aml and Mdsmentioning

confidence: 99%

Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India

Sharma

George

Subhash

et al. 2019

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

This article summarises the main highlights of the abstracts presented at the annual meeting of American Society of Transplantation and Cellular Therapy (ASTCT). The highlights of ASTCT meeting were organised by iNDUS BMT group in Chennai, India. The purpose of the highlight meeting was to educate the students about the latest research in the field of hematopoietic stem cell transplantation and its applicability for the developing country perspective.

show abstract

Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens

Cited by 2 publications

References 0 publications

In MDS, is higher risk higher reward?

In MDS, is higher risk higher reward?

Summary of the Highlights of 2019 ASTCT Meeting by iNDUS BMT Group at Chennai, India

Contact Info

Product

Resources

About